ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Chemotherapy vs Ibrutinib for Frontline Treatment of Chronic Lymphocytic Leukemia

Chemotherapy vs Ibrutinib for Frontline Treatment of Chronic Lymphocytic Leukemia

 

In this video, Susan O’Brien, MD, of the University of California Irvine Medical Center, discusses frontline treatment options for patients with newly diagnosed chronic lymphocytic leukemia (CLL). In order to provide personalized therapy for patients, certain factors may determine whether chemotherapy or ibrutinib would be the more appropriate option.

Dr. O’Brien also discusses novel agents approved as second-line therapies for CLL and side effect profiles physicians should consider when recommending treatment.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.